MX2019008698A - Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo. - Google Patents

Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo.

Info

Publication number
MX2019008698A
MX2019008698A MX2019008698A MX2019008698A MX2019008698A MX 2019008698 A MX2019008698 A MX 2019008698A MX 2019008698 A MX2019008698 A MX 2019008698A MX 2019008698 A MX2019008698 A MX 2019008698A MX 2019008698 A MX2019008698 A MX 2019008698A
Authority
MX
Mexico
Prior art keywords
preparation
pyridine derivative
ask1 inhibitor
ask1
disclosed
Prior art date
Application number
MX2019008698A
Other languages
English (en)
Inventor
Yu Tao
Chen Shuhui
Li Ning
Wu Chengde
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of MX2019008698A publication Critical patent/MX2019008698A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se da a conocer en la presente invención un compuesto tal como se muestra en la fórmula (II), un tautómero o una sal farmacéuticamente aceptable del mismo, y también se da a conocer el uso de los mismos en la preparación de un fármaco para tratar una enfermedad asociada con ASK1. (ver formula).
MX2019008698A 2017-01-22 2018-01-22 Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo. MX2019008698A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710054224 2017-01-22
PCT/CN2018/073640 WO2018133866A1 (zh) 2017-01-22 2018-01-22 作为ask1抑制剂的吡啶衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
MX2019008698A true MX2019008698A (es) 2019-09-18

Family

ID=62907792

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008698A MX2019008698A (es) 2017-01-22 2018-01-22 Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo.

Country Status (18)

Country Link
US (1) US11040968B2 (es)
EP (1) EP3572412B1 (es)
JP (1) JP6650552B2 (es)
KR (1) KR102089234B1 (es)
CN (1) CN109071538B (es)
AU (1) AU2018209574B2 (es)
BR (1) BR112019014756B1 (es)
CA (1) CA3050346C (es)
DK (1) DK3572412T3 (es)
EA (1) EA037005B1 (es)
ES (1) ES2870524T3 (es)
MX (1) MX2019008698A (es)
MY (1) MY174821A (es)
PH (1) PH12019501688A1 (es)
PL (1) PL3572412T3 (es)
SG (1) SG11201906579UA (es)
WO (1) WO2018133866A1 (es)
ZA (1) ZA201904737B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3590931A4 (en) * 2017-03-03 2020-11-18 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. AMIDE DERIVATIVE INHIBITOR, PROCESS OF PREPARATION AND APPLICATION
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
WO2018209354A1 (en) 2017-05-12 2018-11-15 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218051A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109400625B (zh) * 2017-08-17 2021-11-12 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN111801314B (zh) 2018-01-02 2023-10-31 西尔洛克治疗公司 Ask1抑制剂化合物及其用途
AU2019262016A1 (en) 2018-05-02 2020-11-19 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
TWI710561B (zh) * 2018-07-20 2020-11-21 大陸商福建廣生堂藥業股份有限公司 作為ask1抑制劑的晶型及其製備方法和應用
CN111107848B (zh) * 2018-08-10 2023-05-23 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
CN111132984A (zh) * 2018-08-14 2020-05-08 江苏豪森药业集团有限公司 凋亡信号调节激酶1抑制剂的盐及其晶型
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN110922407B (zh) * 2018-09-19 2021-11-12 广东东阳光药业有限公司 苯甲酰氨基吡啶衍生物的晶型及其用途
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020151749A1 (zh) * 2019-01-24 2020-07-30 南京明德新药研发有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN110577535B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577536B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577537B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577534B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577541B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577533B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577538B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577539B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577540B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491606B (zh) * 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
UY34573A (es) * 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
EP3083615B1 (en) * 2013-12-20 2019-04-17 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors

Also Published As

Publication number Publication date
AU2018209574B2 (en) 2021-04-08
CN109071538B (zh) 2020-03-17
BR112019014756B1 (pt) 2021-08-10
JP2020504166A (ja) 2020-02-06
ES2870524T3 (es) 2021-10-27
AU2018209574A1 (en) 2019-09-05
US20200031823A1 (en) 2020-01-30
DK3572412T3 (da) 2021-05-25
EA201991693A1 (ru) 2019-12-30
JP6650552B2 (ja) 2020-02-19
MY174821A (en) 2020-05-18
US11040968B2 (en) 2021-06-22
EP3572412A1 (en) 2019-11-27
KR20190110103A (ko) 2019-09-27
EP3572412A4 (en) 2019-11-27
CA3050346A1 (en) 2018-07-26
PL3572412T3 (pl) 2021-09-27
CN109071538A (zh) 2018-12-21
PH12019501688A1 (en) 2020-03-09
ZA201904737B (en) 2020-05-27
KR102089234B1 (ko) 2020-05-15
SG11201906579UA (en) 2019-08-27
BR112019014756A2 (pt) 2020-03-03
WO2018133866A1 (zh) 2018-07-26
EP3572412B1 (en) 2021-03-03
CA3050346C (en) 2020-07-14
EA037005B1 (ru) 2021-01-26

Similar Documents

Publication Publication Date Title
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
PH12018550120A1 (en) Steroid derivative fxr agonist
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
MX2017013797A (es) Inhibidor de janus quinasa.
PH12019500480A1 (en) Pyridine compound
MX2020007265A (es) Derivados de rapamicina.
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
PH12019501955A1 (en) Tri-cycle compound and applications thereof
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
PH12016502246A1 (en) Carboxamide derivatives
MX2021007247A (es) Derivados de rapamicina.
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
PH12019550154A1 (en) Azetidine derivative
PH12020550649A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
PH12021550572A1 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD.